Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
View Patent ↗The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
1. A chimeric anti-α5β1 integrin antibody comprising:
a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 1;
a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 7; and
a constant region, wherein the source of the constant region is a human IgG.
2. The antibody of claim 1 , where the source of the constant region is human IgG4.
3. A pharmaceutical composition comprising the antibody of claim 1 , and a physiologically acceptable carrier.
4. A chimeric anti-α5β1 integrin antibody comprising:
a heavy chain consisting of the amino acid sequence of SEQ ID NO: 25; and
a light chain consisting of the amino acid sequence of SEQ ID NO: 26.
5. A pharmaceutical composition comprising the antibody of claim 4 , and a physiologically acceptable carrier.
6. A chimeric anti-α5β1 integrin antibody comprising:
a heavy chain consisting of the amino acid sequence of SEQ ID NO: 28; and
a light chain consisting of the amino acid sequence of SEQ ID NO: 26.
7. A pharmaceutical composition comprising the antibody of claim 6 , and a physiologically acceptable carrier.
8. A humanized anti-α5β1 integrin antibody comprising:
a heavy chain consisting of the amino acid sequence SEQ ID NO: 31; and
a light chain consisting of the amino acid sequence of SEQ ID NO: 32.
9. A pharmaceutical composition comprising the antibody of claim 8 , and a physiologically acceptable carder.